法布里病
α-半乳糖苷酶
生物标志物
溶酶体贮存病
酶替代疗法
疾病
内科学
突变
诊断准确性
医学
基因
诊断生物标志物
诊断试验
内分泌学
生物
生物化学
儿科
作者
Galina Baydakova,Alexandra Ilyushkina,Sergey Moiseev,Igor Bychkov,Н. В. Никитина,T. A. Buruleva,Ekaterina Zakharova
标识
DOI:10.1016/j.cca.2019.10.031
摘要
Fabry disease (FD [MIM:301500]) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene. Deficient activity of its product, lysosomal enzyme α-galactosidase A (α-Gal A), leads to excessive accumulation of glycosphingolipids in cells of multiple organs. The establishing of the diagnosis is challenge in female patients because of milder clinical manifestation and normal α-Gal A activity. The globotriaosylsphingosine (lysoGb3) is described as a more sensitive diagnostic biomarker for females with pathogenic mutation in the GLA gene. Thus, the aim of this study is to improve the biochemical diagnostic efficiency for FD in females. Here we report the α-Gal A/lysoGb3 ratio as the novel biochemical criteria for diagnosis of female patients with FD, using dried blood spots (DBS) as test samples. It showed 100% sensitivity in distinguishing our group of 35 female patients from control (n = 140). Whereas measurement of α-Gal A and lysoGb3 alone showed 8.6% and 74.4% respectively. A new approach of using the ratio of α-Gal A activity to lysoGb3 concentration in DBS may provide a more accurate screening tool for identification of FD females.
科研通智能强力驱动
Strongly Powered by AbleSci AI